Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Cilastatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,529Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arch Biopartners' Cilastatin To Join PONTIAC Phase II Kidney Injury Trial
    Arch Biopartners' Cilastatin To Join PONTIAC Phase II Kidney Injury Trial

    02 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/02/2923541/0/en/Arch-Biopartners-Cilastatin-Drug-Candidate-to-Participate-in-the-PONTIAC-Phase-II-Trial-Targeting-Acute-Kidney-Injury-Caused-by-Drug-Toxins.html

    GLOBENEWSWIRE
    02 Aug 2024
    Share Share
    Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin
    Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin

    27 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/27/2835883/0/en/Arch-Biopartners-Has-Pre-IND-Meeting-With-FDA-to-Discuss-Repurposing-Cilastatin-as-a-New-Treatment-to-Prevent-Acute-Kidney-Injury.html

    GLOBENEWSWIRE
    27 Feb 2024
    Share Share
    Merck defends antibiotic's approval from 2019
    Merck defends antibiotic's approval from 2019

    17 May 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/merck-defends-antibiotics-approval-from-2019-as-bmj-investigation-points-to-decline-in-fda-standards/

    Zachary Brennan ENDPTS
    17 May 2023
    Share Share
    Enforcement Report - Week of February 22, 2023
    Enforcement Report - Week of February 22, 2023

    22 Feb 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2023-51785.pdf

    FDA
    22 Feb 2023
    Share Share
    Merck is shutting the doors at a 300-person plant in PA
    Merck is shutting the doors at a 300-person plant in PA

    25 Mar 2022

    // F. Kansteiner FIERCEPHARMA

    https://www.fiercepharma.com/pharma/merck-telegraphs-closure-pa-antibiotics-plant-employs-300

    F. Kansteiner FIERCEPHARMA
    25 Mar 2022
    Share Share
    FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment
    FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment

    05 Jun 2020

    // MERCK

    https://investors.merck.com/news/press-release-details/2020/FDA-Approves-Mercks-RECARBRIO-imipenem-cilastatin-and-relebactam-for-the-Treatment-of-Adults-with-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP/default.aspx

    MERCK
    05 Jun 2020
    Share Share